X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with SUVEN LIFE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs SUVEN LIFE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA SUVEN LIFE AJANTA PHARMA/
SUVEN LIFE
 
P/E (TTM) x 24.9 19.2 130.2% View Chart
P/BV x 10.3 3.6 289.3% View Chart
Dividend Yield % 0.6 1.1 55.4%  

Financials

 AJANTA PHARMA   SUVEN LIFE
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
SUVEN LIFE
Mar-16
AJANTA PHARMA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs1,720339 508.1%   
Low Rs1,103144 763.9%   
Sales per share (Unadj.) Rs194.639.2 495.9%  
Earnings per share (Unadj.) Rs45.27.5 606.0%  
Cash flow per share (Unadj.) Rs50.38.8 573.2%  
Dividends per share (Unadj.) Rs8.002.00 400.0%  
Dividend yield (eoy) %0.60.8 68.4%  
Book value per share (Unadj.) Rs132.049.0 269.5%  
Shares outstanding (eoy) m88.77127.28 69.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.36.2 117.9%   
Avg P/E ratio x31.232.4 96.5%  
P/CF ratio (eoy) x28.127.5 102.0%  
Price / Book Value ratio x10.74.9 216.9%  
Dividend payout %17.726.8 66.0%   
Avg Mkt Cap Rs m125,29930,732 407.7%   
No. of employees `000NA1.0 0.0%   
Total wages/salary Rs m2,570416 617.2%   
Avg. sales/employee Rs ThNM5,236.1-  
Avg. wages/employee Rs ThNM436.5-  
Avg. net profit/employee Rs ThNM995.5-  
INCOME DATA
Net Sales Rs m17,2754,995 345.8%  
Other income Rs m166194 85.9%   
Total revenues Rs m17,4425,189 336.1%   
Gross profit Rs m5,8071,233 471.1%  
Depreciation Rs m451167 269.5%   
Interest Rs m4954 90.2%   
Profit before tax Rs m5,4741,205 454.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,460255 572.5%   
Profit after tax Rs m4,014950 422.7%  
Gross profit margin %33.624.7 136.2%  
Effective tax rate %26.721.2 126.0%   
Net profit margin %23.219.0 122.2%  
BALANCE SHEET DATA
Current assets Rs m7,6394,986 153.2%   
Current liabilities Rs m2,7151,042 260.5%   
Net working cap to sales %28.579.0 36.1%  
Current ratio x2.84.8 58.8%  
Inventory Days Days4361 70.9%  
Debtors Days Days7939 201.0%  
Net fixed assets Rs m6,9143,126 221.2%   
Share capital Rs m177127 139.0%   
"Free" reserves Rs m11,4423,717 307.8%   
Net worth Rs m11,7216,236 187.9%   
Long term debt Rs m149432 34.4%   
Total assets Rs m14,8148,079 183.4%  
Interest coverage x112.923.2 486.3%   
Debt to equity ratio x00.1 18.3%  
Sales to assets ratio x1.20.6 188.6%   
Return on assets %27.412.4 220.7%  
Return on equity %34.215.2 224.9%  
Return on capital %46.518.9 246.5%  
Exports to sales %55.187.5 63.0%   
Imports to sales %6.012.2 49.1%   
Exports (fob) Rs m9,5274,371 218.0%   
Imports (cif) Rs m1,038611 169.9%   
Fx inflow Rs m10,4224,666 223.3%   
Fx outflow Rs m1,678942 178.1%   
Net fx Rs m8,7443,724 234.8%   
CASH FLOW
From Operations Rs m3,264922 354.0%  
From Investments Rs m-2,093-619 337.9%  
From Financial Activity Rs m-1,186-698 169.8%  
Net Cashflow Rs m-15-396 3.7%  

Share Holding

Indian Promoters % 73.8 63.4 116.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 0.0 -  
FIIs % 7.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 36.5 46.6%  
Shareholders   20,968 37,287 56.2%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   DR. DATSONS LABS  STRIDES SHASUN LTD  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS